The effect of the carvedilol-loaded BiodivYsioTM DD stent on the inhibition of neointimal proliferation in a porcine coronary stent restenosis model.
- Author:
Weon KIM
1
;
Myung Ho JEONG
;
Kwang Soo CHA
;
Seung Hyun LEE
;
Young Joon HONG
;
Ju Han KIM
;
Young Keun AHN
;
Ok Young PARK
;
Mu Hyun KIM
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article
- Keywords:
Stents;
Receptors;
Restenosis
- MeSH:
Animals;
Constriction, Pathologic;
Coronary Vessels;
Humans;
Hyperplasia;
Immersion;
Methanol;
Myocytes, Smooth Muscle;
Rats;
Stents*
- From:Korean Journal of Medicine
2004;66(1):48-57
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Carvedilol is a beta- and alpha-receptor blocker, a direct inhibitor of smooth muscle cell proliferation and migration, and produces a significant suppression of neointimal hyperplasia in rat carotid injury model. We tested whether carvedilol stent coating is effective in preventing neointimal formation in a porcine model of stent restenosis. METHODS: BiodivYsio phosphorylcholine-coated stents were dip-coated with carvedilol at the concentrations of 0, 7, 96 and 154 micrometer/stent by the immersion in a methanolic carvedilol followed by the evaporation of the solvent. Thirty-two stents, 8 stents per each concentration, were deployed in the porcine coronary arteries. The treatment effect was assessed at 28 days after stent implantation. RESULTS: Angiographic minimal lumen diameter and late loss index were similar among the four groups. On histomorphometry, neointimal area decreased by 58% and lumen area increased by 20%, resulting in a 58% reduction of percent in-stent stenosis in 7 micrometer carvedilol/stent (p=0.002, 0.008 and 0.004, respectively, 7 micrometer vs. 0 micrometer carvedilol/stent). Modest change in neointimal and lumen area was observed in 96 and 154 micrometer carvedilol/stent. A proliferating nuclear cell antigen-positive cells was noted 7.78 +/- 2.97% in 7 micrometer carvedilol/stent vs. 17.82 +/- 1.45% in 0 micrometer carvedilol/stent (p=0.0001). CONCLUSION: A Low dose carvedilol stent coating produces a significant inhibition of neointimal hyperplasia in a porcine model of stent restenosis. This study provides a potential therapeutic benefit of carvedilol coating in the prevention of human stent restenosis.
